A responsible read on healthRX’s in-depth resource starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.
Last October, a pharmacist named David in Raleigh, North Carolina, pulled up a certificate of analysis for a lot of compounded semaglutide his 503A pharmacy had just received. The purity number came back at 97.2%. Acceptable. But the lot before it, from a different supplier, had come in at 91.6%, which was not. “That six-point gap is the whole ballgame,” he told me. “A patient doesn’t see the certificate. They see a vial that looks identical. The ethics of compounding are in the paperwork nobody asks for.”
He’s right. And most of the conversation about compounding ethics never gets this granular.
The decisions that actually matter
When people talk about ethics in 503A and 503B compounding, they tend to reach for abstractions. Trust. Transparency. Patient-centered care. Those words are fine. They’re also useless without specifics.
Here is what ethics in compounding actually looks like on a Tuesday afternoon: Where did the active pharmaceutical ingredient come from? What sterility testing protocols does the pharmacy run, and how often? How are adverse events tracked and reported? How does the pharmacy’s marketing language avoid implying that a compounded product is the same as an FDA-approved one? Is the prescriber who signed off financially entangled with the pharmacy filling the script?
Each of those is a binary. The pharmacy either does it or doesn’t. The prescriber either discloses or doesn’t. There’s remarkably little gray area.
The distinction between 503A and 503B facilities matters here in ways that most patients never encounter. A 503A pharmacy compounds in response to individual patient prescriptions. A 503B outsourcing facility can compound in bulk without patient-specific prescriptions but faces stricter FDA oversight, including current good manufacturing practice (cGMP) requirements and regular FDA inspections. A 2023 report from the Pew Charitable Trusts found that compliance rates among 503B facilities varied widely, with some facilities going years between inspections due to resource constraints at the FDA. The regulatory category a pharmacy operates under shapes its obligations, but it does not automatically guarantee that those obligations are being met.
Sourcing and the certificate nobody reads
Reputable compounding pharmacies source their active pharmaceutical ingredients from FDA-registered facilities. For every lot, they should hold a certificate of analysis documenting identity, purity, and the absence of relevant contaminants. This is table stakes, not a bonus feature.
The catch is that patients almost never ask for it. And some pharmacies count on that. A pharmacy that can’t produce a current certificate for a given lot is, bluntly, not meeting the standard that injectable medication demands. If you’re injecting something weekly, you should know what’s in the vial. Asking for the certificate is not rude. It’s the minimum.
Consider the specifics of what a certificate of analysis should show for a compounded GLP-1 agonist preparation. At a minimum: assay results confirming that the active ingredient concentration falls within an acceptable range (typically 90 to 110 percent of the labeled amount), endotoxin testing results for injectables (USP chapter 85 sets the bacterial endotoxin threshold), sterility test results per USP chapter 71, and a clear identification of the API supplier and the manufacturing site’s FDA registration number. If any of those fields are missing, blank, or described only in vague terms, that is a concrete red flag, not a bureaucratic technicality.
A 2022 analysis published in the Journal of the American Pharmacists Association examined certificates of analysis from multiple compounding pharmacies and found inconsistencies in how purity was reported, with some certificates omitting impurity profiles entirely. The authors concluded that standardization of certificate formats across the compounding sector would materially improve patient safety. Until that standardization happens, the burden falls on patients and prescribers to read what they receive and ask about what they don’t.
Who’s paying whom (and whether you’ll ever find out)
Financial conflicts of interest between prescribers and compounding pharmacies are not theoretical. They’re structural. Ownership stakes, referral arrangements, revenue-sharing agreements with telehealth platforms: all of these can bias the prescribing decision in ways the patient never sees.
The ethical standard here isn’t that these arrangements can’t exist. It’s that they have to be disclosed. A program that documents its financial relationships and provides them on request is operating differently from a program that buries its ownership structure behind three layers of LLC filings. Patients should ask. If the answer is vague, that tells you something.
The scenario plays out more often than most people realize. A telehealth platform advertises compounded semaglutide at a low monthly price. The patient signs up, sees a clinician for a brief video visit, gets a prescription. What the patient does not see: the telehealth platform owns the pharmacy, or has an exclusive dispensing agreement with a single compounding facility, or the prescribing clinician receives a per-prescription bonus. None of that is necessarily illegal. But all of it influences which medication gets prescribed, at what dose, and from which source. A 2024 commentary in JAMA Internal Medicine noted that the rapid growth of direct-to-consumer telehealth prescribing for GLP-1 agonists has outpaced the development of conflict-of-interest disclosure standards specific to this model. That gap is real and currently unfilled.
Sterile compounding: what USP 797 actually requires
USP 797 sets the framework for sterile compounding, and it’s detailed. Environmental monitoring, sterility testing on finished preparations, stability testing to confirm potency over the labeled shelf life. A pharmacy preparing injectable peptides should be able to describe its monitoring program in specific, concrete terms.
Here’s the thing: willingness to describe that program in detail is itself one of the best signals available. Pharmacies that talk openly about their clean-room protocols, their testing cadence, and their out-of-spec rejection rates are generally the ones with nothing to hide. Pharmacies that deflect those questions tend to have reasons for deflecting.
The revised USP 797 standards, which have gone through multiple rounds of public comment and revision, tighten requirements around beyond-use dating. A 503A pharmacy that assigns a 30-day beyond-use date to a sterile injectable without supporting stability data is not following the standard. That matters because peptide degradation in a compounded semaglutide vial directly affects the dose a patient actually receives. A vial that started at the labeled concentration and degrades by 15 percent over its shelf life is delivering a meaningfully different dose by the last injection. Stability testing exists to prevent exactly this scenario, and pharmacies that skip it are making a choice with clinical consequences.
Environmental monitoring is another area where the gap between compliant and non-compliant pharmacies is wide. Compliant facilities conduct viable and non-viable air sampling inside the ISO-classified clean room, surface sampling of critical work areas, and gloved fingertip testing of compounding personnel, all at defined intervals. If a pharmacy cannot tell you when its last environmental monitoring was performed and what the results were, that silence is informative.
What patients should hear before the first injection
Ethical communication starts with a simple fact that too many programs soft-pedal: a compounded preparation is not the same as an FDA-approved product. Full stop. It also includes honest disclosure of the boxed warnings that apply to the active ingredient (including the medullary thyroid carcinoma warning for GLP-1 agonists), the contraindications a prescriber should screen for at intake, and the absence of FDA approval for the specific compounded formulation.
None of this should be buried in a Terms of Service document that runs 14 pages. It belongs in the intake conversation, spoken out loud, before someone rolls up their sleeve.
The intake screening itself deserves scrutiny. A responsible program screens for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, history of pancreatitis, severe gastrointestinal disease, and current use of other medications that affect gastric motility or blood glucose. Programs that skip these questions, or reduce the intake to a checkbox form with no clinical follow-up, are cutting corners where the clinical stakes are highest.
Adverse event reporting is not optional
This one is straightforward and still gets botched. When a patient experiences a reportable adverse event, both the prescribing clinician and the dispensing pharmacy have obligations to document and submit through the appropriate channels. This is a clinical function, not a PR liability.
Programs that treat adverse-event reporting as routine tend to be the same programs that catch safety signals early and adjust dosing protocols before small problems become large ones. Programs that treat it as a threat to their marketing tend to be the ones you read about later in FDA warning letters.
The FDA’s MedWatch system is the primary channel for reporting adverse events associated with compounded medications. Between 2020 and 2024, FDA received a notable increase in adverse event reports related to compounded injectable peptides, including reports of sterility failures, incorrect concentrations, and allergic reactions to inactive ingredients. Each report is a data point. Programs that systematically file reports contribute to the safety infrastructure that protects every patient using these medications. Programs that quietly absorb complaints and move on are free-riding on the reporting of others.
Marketing claims that should make you suspicious
A short, incomplete list of claims that reputable compounding programs avoid:
- That a compounded preparation is “equivalent to” or “interchangeable with” an FDA-approved product.
- That a compounded peptide is “FDA-approved.”
- That clinical trial results from branded semaglutide (the STEP trials, the SELECT trial) apply directly to the compounded version.
- That a compound has “the same safety profile” as the branded version without acknowledging the differences in manufacturing oversight and excipient formulation.
Each of these is misleading. The third one is especially common and especially slippery, because the active ingredient is the same, but the formulation, the manufacturing controls, and the regulatory oversight are not. Responsible programs draw this distinction clearly. Irresponsible ones blur it on purpose.
notably, what a defensible marketing claim looks like. A program can accurately state that it uses the same active pharmaceutical ingredient as the branded product. It can describe its sourcing and testing practices. It can cite published literature on the molecule while clearly noting that those studies were conducted with FDA-approved formulations. The line between accurate and misleading is not actually that hard to find. It just requires the willingness to draw it.
See also: Lighting the Future: Smart Choices for Modern LED Strip Solutions
How to hold a program accountable (without a law degree)
Patients have more leverage than they think. Ask for documentation in writing. Check state board of pharmacy public records (these are searchable online in most states). Read the program’s clinical policies, not just its homepage. Ask direct questions about pricing, refund policy, and what happens to your care if the program shuts down.
Programs that answer those questions in detail have already done the internal work. Programs that resist them probably haven’t.
A practical checklist for any patient evaluating a compounding program:
- Can the pharmacy produce a current certificate of analysis for the specific lot dispensed to you?
- Is the pharmacy licensed in your state and in good standing with the state board of pharmacy?
- Does the prescribing clinician disclose any financial relationship with the pharmacy or platform?
- Does the program screen for contraindications before prescribing?
- Is there a documented process for adverse event reporting?
- Does the pharmacy follow USP 797 for sterile compounding, and can it describe its testing protocols?
- Does the program’s marketing clearly distinguish compounded preparations from FDA-approved products?
If the answer to any of those is “no” or “I don’t know,” that is useful information.
The long view
The honest ethical case for compounded semaglutide is narrower than its loudest advocates claim and broader than its harshest critics allow. Compounding has provided a legitimate release valve during a documented shortage. It has expanded access for patients whose insurance won’t cover branded alternatives. At its best, it has operated to standards that approach what commercial manufacturing produces.
The ethical case requires that those standards hold even after the spotlight moves on. Five-year follow-up data are accumulating. Retention curves are starting to appear. The comparative outcomes of different programs are being studied. The clinical recommendations of 2028 will look at least somewhat different from those of 2026, and patients starting therapy now are, in a real sense, contributing to that evidence base. That’s worth taking seriously.
For a longer overview bringing together the trial data, the regulatory framing, and the practical questions a patient should ask, HealthRX’s in-depth resource is a useful companion to this piece. As a LegitScript-certified platform, HealthRX operates within a verification framework that addresses many of the transparency concerns discussed here.
My genuinely held opinion: the compounding pharmacies that survive the next regulatory tightening will be the ones that operated as though the tightening had already happened. The rest are borrowing time.
Decisions in this area should be made carefully, with a prescribing clinician, and with a clear-eyed view of the published evidence.
Not FDA-approved. HealthRX is not a medical practice. Individual results vary.
